From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculati…
Eli Lilly’s blockbuster antidepressant Cymbalta can now also be marketed as a treatment for chronic musculoskeletal pain, such as osteoarthritis and lower back pain, following FDA approval yesterday.
Continue r…
Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK’d, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are s…